Heart failure & cardiomyopathies
Efficacy and Safety of the Kidney Function–Based Finerenone Dosing Strategy Used in FINEARTS-HF
Authors' conclusion
In FINEARTS-HF, an eGFR-based dosing strategy allowed effective and safe use of finerenone in patients with heart failure with mildly reduced ejection fraction/ heart failure with preserved ejection fraction with a baseline eGFR as low as 25 mL/min/1.73 m2.
Study context
- Population
- Patients with HF with mildly reduced or preserved EF (FINEARTS-HF)99.8% analyzable
- Participants
- 5,986 patients
- Comparison
- Finerenone vs placebo, by estimated glomerular filtration rate (eGFR)-based dosing stratum
- Higher eGFR/high-dose stratumn = 3,159
- Lower eGFR/low-dose stratumn = 2,827
- Primary endpoint
- Composite of:
- Total (first and recurrent) HF events
- CV death
Methodological detailsprespecified analysis, placebo-controlled
- Prespecified analysis
- Placebo-controlled
Primary result
As reported in the abstract
Finerenone vs PlaceboRate ratio (95% CI)
Higher eGFR/high-dose stratum
0.77(0.63–0.94)
Lower eGFR/low-dose stratum
0.87(0.74–1.03)
Further findings
Mean achieved dose
- Higher eGFR/high-dose stratum, finerenone
- 32.3 ± 9.1 mg
- Higher eGFR/high-dose stratum, placebo
- 34.4 ± 7.8 mg
- Lower eGFR/low-dose stratum, finerenone
- 15.6 ± 4.3 mg
- Lower eGFR/low-dose stratum, placebo
- 16.7 ± 4.0 mg
- Mean ± SD
Components of primary outcome and all-cause death
- Consistent benefits across dosing strata
Safety
Safety, incl. hypokalemia
- Safety consistent between strata, except greater reduction in odds of hypokalemia with finerenone vs placebo in higher eGFR/high-dose stratum
- P for interaction < 0.01
Original publication
Efficacy and Safety of the Kidney Function–Based Finerenone Dosing Strategy Used in FINEARTS-HF. JACC Heart Fail. Published 4 February 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →